Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)
Status:
RECRUITING
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
Phase I study with dose-escalation and expansion evaluating the safety and efficacy of oral Arsenic (ATO) in low-risk Myelodysplastic Syndromes having failed to Erythropoiesis Stimulating Agents and Luspatercept (or ineligible for the latter).